Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Andersen-Tawil Syndrome (ATS) is a rare genetic disorder that causes episodes of muscle
weakness, potentially life-threatening changes in heart rhythm, and skeletal developmental
abnormalities. The cause of some ATS cases remains unknown, and no specific treatments have
been established. The purpose of this study is to determine whether potassium supplements
and/or the medication acetazolamide affect the duration of muscle weakness and heart rhythm
abnormalities in people with ATS.
Phase:
Phase 1
Details
Lead Sponsor:
University of Rochester
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS) Office of Rare Diseases (ORD) Rare Diseases Clinical Research Network